Benjamin K Hendricks1, Nader Sanai1, Walter Stummer2. 1. Barrow Neurological Institute, Phoenix, AZ, USA. 2. Department of Neurosurgery, University of Münster, Münster, Germany. Walter.Stummer@ukmuenster.de.
Abstract
INTRODUCTION: Fluorescence guided surgery has developed over the last 2 decades as a formidable augmentation strategy to promote maximal safe resection and diagnostic accuracy within gliomas. The majority of the literature evidence supporting this modality utilizes 5-aminolevulinic acid in the setting of high-grade gliomas. The role for fluorescence guided surgery in low-grade gliomas is less well defined. RESULTS: This review describes the existing literature discussing the utilization of 5-aminolevulinic acid for fluorescence guided surgery in low-grade gliomas, including its pertinence in identification of anaplastic foci and potential role in guiding resection following combination with augmentation strategies for detection. CONCLUSION: The advance in operative technology and growth of research analyzing 5-aminolevulinic acid will continue to enhance the role of fluorescence guided surgery within the standard of surgical management for low-grade gliomas.
INTRODUCTION: Fluorescence guided surgery has developed over the last 2 decades as a formidable augmentation strategy to promote maximal safe resection and diagnostic accuracy within gliomas. The majority of the literature evidence supporting this modality utilizes 5-aminolevulinic acid in the setting of high-grade gliomas. The role for fluorescence guided surgery in low-grade gliomas is less well defined. RESULTS: This review describes the existing literature discussing the utilization of 5-aminolevulinic acid for fluorescence guided surgery in low-grade gliomas, including its pertinence in identification of anaplastic foci and potential role in guiding resection following combination with augmentation strategies for detection. CONCLUSION: The advance in operative technology and growth of research analyzing 5-aminolevulinic acid will continue to enhance the role of fluorescence guided surgery within the standard of surgical management for low-grade gliomas.
Authors: A Nabavi; P M Black; D T Gering; C F Westin; V Mehta; R S Pergolizzi; M Ferrant; S K Warfield; N Hata; R B Schwartz; W M Wells; R Kikinis; F A Jolesz Journal: Neurosurgery Date: 2001-04 Impact factor: 4.654
Authors: N Sadeghi; I Salmon; C Decaestecker; M Levivier; T Metens; D Wikler; V Denolin; S Rorive; N Massager; D Baleriaux; S Goldman Journal: AJNR Am J Neuroradiol Date: 2007-03 Impact factor: 3.825
Authors: Matthew J McGirt; Kaisorn L Chaichana; Frank J Attenello; Jon D Weingart; Khoi Than; Peter C Burger; Alessandro Olivi; Henry Brem; Alfredo Quinoñes-Hinojosa Journal: Neurosurgery Date: 2008-10 Impact factor: 4.654
Authors: David Reichert; Mikael T Erkkilä; Gerhard Holst; Nancy Hecker-Denschlag; Marco Wilzbach; Christoph Hauger; Wolfgang Drexler; Johanna Gesperger; Barbara Kiesel; Thomas Roetzer; Angelika Unterhuber; Georg Widhalm; Rainer A Leitgeb; Marco Andreana Journal: Biomed Opt Express Date: 2020-02-26 Impact factor: 3.732
Authors: Conor C Horgan; Mads S Bergholt; May Zaw Thin; Anika Nagelkerke; Robert Kennedy; Tammy L Kalber; Daniel J Stuckey; Molly M Stevens Journal: J Biomed Opt Date: 2021-03 Impact factor: 3.170
Authors: Marco Riva; Tommaso Sciortino; Riccardo Secoli; Ester D'Amico; Sara Moccia; Bethania Fernandes; Marco Conti Nibali; Lorenzo Gay; Marco Rossi; Elena De Momi; Lorenzo Bello Journal: Cancers (Basel) Date: 2021-03-03 Impact factor: 6.639